Advertisement

Comparison of antinociceptive effects of plain lidocaine versus lidocaine complexed with hydroxypropyl-β-cyclodextrin in animal models of acute and persistent orofacial pain

  • Stéphani Batista de Oliveira
  • Erika Ivanna Araya
  • Eder Gambeta
  • Luiz Eduardo Nunes Ferreira
  • Michele Franz-Montan
  • Rafaela Franco Claudino
  • Juliana Geremias ChichorroEmail author
Original Article
  • 58 Downloads

Abstract

Herein, it was investigated whether a complex of lidocaine with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) would present a better antinociceptive profile in vivo when compared with plain lidocaine in models of orofacial pain. Plain lidocaine (LDC) and complexed lidocaine (LDC:HP-β-CD) were initially evaluated in vitro to determine the release rate of the two formulations. Subsequently, the effect of both formulations was evaluated in independent groups of rats submitted to the orofacial formalin test, induction of facial heat hyperalgesia by capsaicin and carrageenan, and induction of facial heat and mechanical hyperalgesia by constriction of the infraorbital nerve. LDC:HP-β-CD led to a reduction in the lidocaine release assessed in the in vitro release assay compared to plain LDC. Both formulations presented an antinociceptive effect in all models, but LDC:HP-β-CD showed a better effect in the second phase of the formalin response, in carrageenan-induced heat hyperalgesia, and in the heat hyperalgesia associated to infraorbital nerve constriction. Our results show that complexation improved in vivo antinociceptive effects of LDC, but further studies are necessary to elucidate what properties contribute to the better effect of the complexed formulation on this models and/or what characteristics of the pain model facilitate the action of the complexed formulation.

Keywords

Lidocaine Trigeminal neuropathic pain Capsaicin Carrageenan Formalin Hyperalgesia 

Notes

Author contribution

JGC and RFC conceived and designed research. SBO, EIA, and EG conducted the in vivo experiments. LENF and MFM prepared lidocaine complexed formulation and conducted the in vitro assay. JGC analyzed data and wrote the manuscript. All authors read, revised, and approved the manuscript.

Funding

This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil (CAPES) - Finance Code 001.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures were conducted in accordance with the Institutional Committee on the Ethical Use of Animals (authorization no. 1039) and performed in accordance with ethical guidelines, including the policies and recommendations of the International Association for the Study of Pain and according to the recommendations of the Brazilian Agency CONCEA (National Council of Control in Experimental Animals).

Supplementary material

210_2018_1609_Fig5_ESM.png (616 kb)
Supplementary Figure 1

Experimental procedures timeline. In the formalin test animals received plain lidocaine (LDC, 2% in 50 μL), complexed lidocaine (LDC:HP-β-CD, 2% in 50 μL) or vehicle (VEH, 50 μL) into the right upper lip, and after 10 minutes, formalin (FOR, 2.5% in 50 μL) or saline (SAL, 50 μL) in the same site. The grooming response was assessed for 30 min (first phase: 0-3 minutes, second phase: 12-30 min). In the capsaicin test, heat hyperalgesia was assessed (BL), and animals was treated with plain lidocaine (LDC, 2% in 50 μL), complexed lidocaine (LDC:HP-β-CD, 2% in 50 μL) or vehicle (VEH, 50 μL) into the right upper lip, and after 10 minutes, capsaicin (CAP, 3 μg in 50 μL) or saline (SAL, 50 μL) was injected in the same site. Heat hyperalgesia was measured 0.5, 1, 2, 3 and 4 h after CAP/SAL injection. In the Carrageenan test, animals were subjected to the same procedure, but the treatments were performed 150 min after carrageenan (CAR, 100 μg in 50 μL) or saline (SAL, 50 μL) into the right upper lip. Heat and mechanical hyperalgesia were evaluated 5 and 15 days, respectively, after CION, as well as hourly after treatments with plain lidocaine (LDC, 2% in 50 μL), complexed lidocaine (LDC:HP-β-CD, 2% in 50 μL) or vehicle (VEH, 50 μL) into the right upper lip. (PNG 615 kb)

210_2018_1609_MOESM1_ESM.tif (119 kb)
High resolution image (TIF 119 kb)
210_2018_1609_Fig6_ESM.png (50 kb)
Supplementary Figure 2

Effect of plain lidocaine (LDC) and lidocaine complexed with 2-hydroxypropyl-β-cyclodextrin (LDC:HP-β-CD) in control animals (related to Fig 2). Animals was pre-treated with plain lidocaine (LDC, 2% in 50 μL) or complexed lidocaine (LDC:HP-β-CD, 2% in 50 μL) into the right upper lip, and after 10 minutes, vehicle (VEH, 50 μL) was injected in the same site. The grooming response was assessed for 30 minutes after VEH injection, and the first phase was considered from 0-3 minutes and the second phase was considered from 12-30 minutes. Data are expressed as mean ± SEM. Two-way ANOVA with repeated measures followed by the Bonferroni post hoc test (n=9-11). (PNG 50 kb)

210_2018_1609_MOESM2_ESM.tif (36 kb)
High resolution image (TIF 36 kb)
210_2018_1609_Fig7_ESM.png (38 kb)
Supplementary Figure 3

Effect of plain lidocaine (LDC) and lidocaine complexed with 2-hydroxypropyl-β-cyclodextrin (LDC:HP-β-CD) in control animals (related to Fig 3). Heat hyperalgesia baseline (BL) was assesses and animals was treated with plain lidocaine (LDC, 2% in 50 μL) or complexed lidocaine (LDC:HP-β-CD, 2% in 50 μL) into the right upper lip, and 10 or 150 minutes later they were treated with capsaicin vehicle (50 μL, Panel A) or with carrageenan vehicle (50 μL, Panel B), respectively. Data are expressed as mean ± SEM. Two-way ANOVA with repeated measures followed by the Bonferroni post hoc test (n=6-10). (PNG 37 kb)

210_2018_1609_MOESM3_ESM.tif (28 kb)
High resolution image (TIF 27 kb)
210_2018_1609_Fig8_ESM.png (40 kb)
Supplementary Figure 4

Effect of plain lidocaine (LDC) and lidocaine complexed with 2-hydroxypropyl-β-cyclodextrin (LDC:HP-β-CD) in SHAM animals (related to Fig 4). Heat or mechanical hyperalgesia baseline (BL) was assessed and SHAM surgery was performed. The heat and mechanical hyperalgesia was measured 5 or 15 days after surgery, respectively. Animals was treated with plain lidocaine (LDC, 2% in 50 μL) or complexed lidocaine (LDC:HP-β-CD, 2% in 50 μL) into the right upper lip, and heat or mechanical hyperalgesia (Panel A and B, respectively) was assessed for up to 4 hours after treatment. Data are expressed as mean ± SEM. Two-way ANOVA with repeated measures followed by the Bonferroni post hoc test (n=6-10). (PNG 40 kb)

210_2018_1609_MOESM4_ESM.tif (28 kb)
High resolution image (TIF 28 kb)

References

  1. Almeida RT, Duarte ID (2008) Nitric oxide/cGMP pathway mediates orofacial antinociception induced by electroacupuncture at the St36 acupoint. Brain Res 1188:54–60CrossRefGoogle Scholar
  2. Anirudhan TS, Nair SS, Nair AS (2016) Fabrication of a bioadhesive transdermal device from chitosan and hyaluronic acid for the controlled release of lidocaine. Carbohydr Polym 152:687–698CrossRefGoogle Scholar
  3. Araujo DR, Braga Ade F, Moraes CM, Fraceto LF, Paula E (2006) Complexation of 50% enantiomeric excess (S75-R25) bupivacaine with cyclodextrins and spinal block anesthesia in rats. Rev Bras Anestesiol 56:495–506Google Scholar
  4. Araya EI, Nones CFM, Ferreira LEN, Kopruszinski CM, Cunha JMD, Chichorro JG (2017) Role of peripheral and central TRPV1 receptors in facial heat hyperalgesia in streptozotocin-induced diabetic rats. Brain Res 1670:146–155CrossRefGoogle Scholar
  5. Becker DE, Reed KL (2012) Local anesthetics: review of pharmacological considerations. Anesth Prog 59:90–101 quiz 102-103CrossRefGoogle Scholar
  6. Berk T, Silberstein SD (2018) The use and method of action of intravenous lidocaine and its metabolite in headache disorders. Headache 58:783–789CrossRefGoogle Scholar
  7. Braga MA, Martini MF, Pickholz M, Yokaichiya F, Franco MK, Cabeca LF, Guilherme VA, Silva CM, Limia CE, de Paula E (2016) Clonidine complexation with hydroxypropyl-beta-cyclodextrin: from physico-chemical characterization to in vivo adjuvant effect in local anesthesia. J Pharm Biomed Anal 119:27–36CrossRefGoogle Scholar
  8. Brederson JD, Kym PR, Szallasi A (2013) Targeting TRP channels for pain relief. Eur J Pharmacol 716:61–76CrossRefGoogle Scholar
  9. Casale R, Symeonidou Z, Bartolo M (2017) Topical treatments for localized neuropathic pain. Curr Pain Headache Rep 21:15CrossRefGoogle Scholar
  10. Cereda CM, Brunetto GB, de Araujo DR, de Paula E (2006) Liposomal formulations of prilocaine, lidocaine and mepivacaine prolong analgesic duration. Can J Anaesth 53:1092–1097CrossRefGoogle Scholar
  11. Chichorro JG, Lorenzetti BB, Zampronio AR (2004) Involvement of bradykinin, cytokines, sympathetic amines and prostaglandins in formalin-induced orofacial nociception in rats. Br J Pharmacol 141:1175–1184CrossRefGoogle Scholar
  12. Chichorro JG, Zampronio AR, Rae GA (2006) Endothelin ET(B) receptor antagonist reduces mechanical allodynia in rats with trigeminal neuropathic pain. Exp Biol Med (Maywood) 231:1136–1140Google Scholar
  13. Chichorro JG, Zampronio AR, Cabrini DA, Franco CR, Rae GA (2009) Mechanisms operated by endothelin ETA and ETB receptors in the trigeminal ganglion contribute to orofacial thermal hyperalgesia induced by infraorbital nerve constriction in rats. Neuropeptides 43:133–142CrossRefGoogle Scholar
  14. Clavelou P, Pajot J, Dallel R, Raboisson P (1989) Application of the formalin test to the study of orofacial pain in the rat. Neurosci Lett 103:349–353CrossRefGoogle Scholar
  15. Dach F, Eckeli AL, Ferreira Kdos S, Speciali JG (2015) Nerve block for the treatment of headaches and cranial neuralgias - a practical approach. Headache 55(Suppl 1):59–71CrossRefGoogle Scholar
  16. Dale GJ, Phillips S, Falk GL (2016) The analgesic efficacy of intravenous lidocaine infusion after laparoscopic fundoplication: a prospective, randomized, double-blind, placebo-controlled trial. Local Reg Anesth 9:87–93CrossRefGoogle Scholar
  17. Dallel R, Raboisson P, Clavelou P, Saade M, Woda A (1995) Evidence for a peripheral origin of the tonic nociceptive response to subcutaneous formalin. Pain 61:11–16CrossRefGoogle Scholar
  18. de Araujo DR, Tsuneda SS, Cereda CM, Del GFCF, Prete PS, Fernandes SA, Yokaichiya F, Franco MK, Mazzaro I, Fraceto LF, de FABA, de Paula E (2008) Development and pharmacological evaluation of ropivacaine-2-hydroxypropyl-beta-cyclodextrin inclusion complex. Eur J Pharm Sci 33:60–71CrossRefGoogle Scholar
  19. de Paula E, Cereda CM, Tofoli GR, Franz-Montan M, Fraceto LF, de Araujo DR (2010) Drug delivery systems for local anesthetics. Recent Pat Drug Deliv Formul 4:23–34CrossRefGoogle Scholar
  20. Derry S, Wiffen PJ, Kalso EA, Bell RF, Aldington D, Phillips T, Gaskell H, Moore RA (2017) Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. Cochrane Database Syst Rev 5:CD008609Google Scholar
  21. Di Stani F, Ojango C, Dugoni D, Di Lorenzo L, Masala S, Delfini R, Bruti G, Simonetti G, Piovesan EJ, Ruggeri AG (2015) Combination of pharmacotherapy and lidocaine analgesic block of the peripheral trigeminal branches for trigeminal neuralgia: a pilot study. Arq Neuropsiquiatr 73:660–664CrossRefGoogle Scholar
  22. Dollo G, Thompson DO, Le Corre P, Chevanne F, Le Verge R (1998) Inclusion complexation of amide-typed local anesthetics with b-cyclodextrin and its derivatives. III. Biopharmaceutics of bupivacaine-SBE7-bCD complex following percutaneous sciatic nerve administration in rabbits. Int J Pharm 164:11–19CrossRefGoogle Scholar
  23. Ferreira LE, Muniz BV, Dos Santos CP, Volpato MC, de Paula E, Groppo FC (2016) Comparison of liposomal and 2-hydroxypropyl-beta-cyclodextrin-lidocaine on cell viability and inflammatory response in human keratinocytes and gingival fibroblasts. J Pharm Pharmacol 68:791–802CrossRefGoogle Scholar
  24. Ferreira LEN, Antunes GBM, Muniz BV, Burga-Sanchez J, de Melo NFS, Groppo FC, Fraceto LF, Volpato MC (2018) Effects of lidocaine and the inclusion complex with 2-hydroxypropyl-beta-cyclodextrin on cell viability and proliferation of oral squamous cell carcinoma. J Pharm Pharmacol 70:874–882CrossRefGoogle Scholar
  25. Fletcher D, Kayser V, Guilbaud G (1996) Influence of timing of administration on the analgesic effect of bupivacaine infiltration in carrageenin-injected rats. Anesthesiology 84:1129–1137CrossRefGoogle Scholar
  26. Franco de Lima RA, de Jesus MB, Saia Cereda CM, Tofoli GR, Cabeca LF, Mazzaro I, Fraceto LF, de Paula E (2012) Improvement of tetracaine antinociceptive effect by inclusion in cyclodextrins. J Drug Target 20:85–96CrossRefGoogle Scholar
  27. Franz-Montan M, Baroni D, Brunetto G, Sobral VR, da Silva CM, Venancio P, Zago PW, Cereda CM, Volpato MC, de Araujo DR, de Paula E, Groppo FC (2015) Liposomal lidocaine gel for topical use at the oral mucosa: characterization, in vitro assays and in vivo anesthetic efficacy in humans. J Liposome Res 25:11–19CrossRefGoogle Scholar
  28. Gambeta E, Kopruszinski CM, Dos Reis RC, Zanoveli JM, Chichorro JG (2016) Evaluation of heat hyperalgesia and anxiety like-behaviors in a rat model of orofacial cancer. Neurosci Lett 619:100–105CrossRefGoogle Scholar
  29. Giordano D, Raso MG, Pernice C, Agnoletti V, Barbieri V (2015) Topical local anesthesia: focus on lidocaine-tetracaine combination. Local Reg Anesth 8:95–100CrossRefGoogle Scholar
  30. Gould S, Scott RC (2005) 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 43:1451–1459CrossRefGoogle Scholar
  31. Hao JX, Yu W, Xu XJ, Wiesenfeld-Hallin Z (1996) Capsaicin-sensitive afferents mediate chronic cold, but not mechanical, allodynia-like behavior in spinally injured rats. Brain Res 722:177–180CrossRefGoogle Scholar
  32. Huang J, Zhang X, McNaughton PA (2006) Modulation of temperature-sensitive TRP channels. Semin Cell Dev Biol 17:638–645CrossRefGoogle Scholar
  33. Hummig W, Kopruszinski CM, Chichorro JG (2014) Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain. J Oral Facial Pain Headache 28:350–359CrossRefGoogle Scholar
  34. Jambhekar SS, Breen P (2016a) Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex. Drug Discov Today 21:356–362CrossRefGoogle Scholar
  35. Jambhekar SS, Breen P (2016b) Cyclodextrins in pharmaceutical formulations II: solubilization, binding constant, and complexation efficiency. Drug Discov Today 21:363–368CrossRefGoogle Scholar
  36. Joo JD, Choi JW, In JH, Jung HS, Lee JA, Kim YS, Kim DW, Yeom JH, Shin EY, Jeon YS (2011) Lidocaine suppresses the increased extracellular signal-regulated kinase/cyclic AMP response element-binding protein pathway and pro-inflammatory cytokines in a neuropathic pain model of rats. Eur J Anaesthesiol 28:106–111CrossRefGoogle Scholar
  37. Kayser V, Guilbaud G (1987) Local and remote modifications of nociceptive sensitivity during carrageenin-induced inflammation in the rat. Pain 28:99–107CrossRefGoogle Scholar
  38. Kissin I, Lee SS, Bradley EL Jr (1998) Effect of prolonged nerve block on inflammatory hyperalgesia in rats: prevention of late hyperalgesia. Anesthesiology 88:224–232CrossRefGoogle Scholar
  39. Lang A, Ben Horin S, Picard O, Fudim E, Amariglio N, Chowers Y (2010) Lidocaine inhibits epithelial chemokine secretion via inhibition of nuclear factor kappa B activation. Immunobiology 215:304–313CrossRefGoogle Scholar
  40. Loftsson T, Duchene D (2007) Cyclodextrins and their pharmaceutical applications. Int J Pharm 329:1–11CrossRefGoogle Scholar
  41. Loftsson T, Masson M (2001) Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 225:15–30CrossRefGoogle Scholar
  42. Menezes Pdos P, Araujo AA, Doria GA, Quintans-Junior LJ, de Oliveira MG, dos Santos MR, de Oliveira JF, Matos Jdo R, Carvalho FM, Alves PB, de Matos IL, dos Santos DA, Marreto RN, da Silva GF, Serafini MR (2015) Physicochemical characterization and analgesic effect of inclusion complexes of essential oil from Hyptis pectinata L. Poit leaves with beta-cyclodextrin. Curr Pharm Biotechnol 16:440–450CrossRefGoogle Scholar
  43. Moraes CM, Abrami P, Araujo DRD, Braga AFA, Issa MG, Ferraz HG, Paula E, Fraceto LF (2007) Characterization of lidocaine:hydroxypropyl-b-cyclodextrininclusion complex. J Incl Phenom Macrocycl Chem 57:313–316CrossRefGoogle Scholar
  44. Motta EM, Chichorro JG, Rae GA (2009) Role of ET(A) and ET(B) endothelin receptors on endothelin-1-induced potentiation of nociceptive and thermal hyperalgesic responses evoked by capsaicin in rats. Neurosci Lett 457:146–150CrossRefGoogle Scholar
  45. Ni J, Wang X, Tang Y, Yang L, Zeng Y, Guo Y (2017) Subcutaneous injection of triamcinolone and lidocaine to prevent postherpetic neuralgia. Pain Physician 20:397–403Google Scholar
  46. Ortiz MP, Godoy MC, Schlosser RS, Ortiz RP, Godoy JP, Santiago ES, Rigo FK, Beck V, Duarte T, Duarte MM, Menezes MS (2016) Effect of endovenous lidocaine on analgesia and serum cytokines: double-blinded and randomized trial. J Clin Anesth 35:70–77CrossRefGoogle Scholar
  47. Pedersen JL, Crawford ME, Dahl JB, Brennum J, Kehlet H (1996) Effect of preemptive nerve block on inflammation and hyperalgesia after human thermal injury. Anesthesiology 84:1020–1026CrossRefGoogle Scholar
  48. Pelissier T, Pajot J, Dallel R (2002) The orofacial capsaicin test in rats: effects of different capsaicin concentrations and morphine. Pain 96:81–87CrossRefGoogle Scholar
  49. Pinto LM, Fraceto LF, Santana MH, Pertinhez TA, Junior SO, de Paula E (2005) Physico-chemical characterization of benzocaine-beta-cyclodextrin inclusion complexes. J Pharm Biomed Anal 39:956–963CrossRefGoogle Scholar
  50. Prado AR, Yokaichiya F, Franco M, Silva C, Oliveira-Nascimento L, Franz-Montan M, Volpato MC, Cabeca LF, de Paula E (2017) Complexation of oxethazaine with 2-hydroxypropyl-beta-cyclodextrin: increased drug solubility, decreased cytotoxicity and analgesia at inflamed tissues. J Pharm Pharmacol 69:652–662CrossRefGoogle Scholar
  51. Provinciali L, Lattanzi S, Chiarlone R, Fogliardi A, Intelligente F, Irace C, Lanzilotta M, Palomba R, Storelli E, Zampi M (2014) Topical pharmacologic approach with 5% lidocaine medicated plaster in the treatment of localized neuropathic pain. Minerva Med 105:515–527Google Scholar
  52. Ramos Campos EV, Silva de Melo NF, Guilherme VA, de Paula E, Rosa AH, de Araujo DR, Fraceto LF (2013) Preparation and characterization of poly (epsilon-caprolactone) nanospheres containing the local anesthetic lidocaine. J Pharm Sci 102:215–226CrossRefGoogle Scholar
  53. Sabatowski R, Bosl I, Konig S, Buchheister B, Meier T, Baron R (2017) Treatment of postherpetic neuralgia with 5% lidocaine medicated plaster in elderly patients - subgroup analyses from three European clinical trials. Curr Med Res Opin 33:595–603CrossRefGoogle Scholar
  54. Shen J, Burgess DJ (2012) Accelerated in-vitro release testing methods for extended-release parenteral dosage forms. J Pharm Pharmacol 64:986–996CrossRefGoogle Scholar
  55. Shir Y, Seltzer Z (1990) A-fibers mediate mechanical hyperesthesia and allodynia and C-fibers mediate thermal hyperalgesia in a new model of causalgiform pain disorders in rats. Neurosci Lett 115:62–67CrossRefGoogle Scholar
  56. Suzuki R, Arai YC, Hamayasu K, Fujita K, Hara K, Yamaguchi T, Sasaguri S (2009) Complex of branched cyclodextrin and lidocaine prolonged the duration of peripheral nerve block. J Anesth 23:295–297CrossRefGoogle Scholar
  57. Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ (2010) Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 6:15CrossRefGoogle Scholar
  58. Tamburin S, Schweiger V, Magrinelli F, Brugnoli MP, Zanette G, Polati E (2014) Effect of 5% lidocaine medicated plaster on pain intensity and paroxysms in classical trigeminal neuralgia. Ann Pharmacother 48:1521–1524CrossRefGoogle Scholar
  59. Tender GC, Li YY, Cui JG (2008) Vanilloid receptor 1-positive neurons mediate thermal hyperalgesia and tactile allodynia. Spine J 8:351–358CrossRefGoogle Scholar
  60. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K (1992) The formalin test: an evaluation of the method. Pain 51:5–17CrossRefGoogle Scholar
  61. Uekama K, Hirayama F, Irie T (1998) Cyclodextrin drug carrier systems. Chem Rev 98:2045–2076CrossRefGoogle Scholar
  62. Vos BP, Strassman AM, Maciewicz RJ (1994) Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat’s infraorbital nerve. J Neurosci 14:2708–2723CrossRefGoogle Scholar
  63. Wang CF, Pancaro C, Gerner P, Strichartz G (2011) Prolonged suppression of postincisional pain by a slow-release formulation of lidocaine. Anesthesiology 114:135–149CrossRefGoogle Scholar
  64. Wei Y, Nedley MP, Bhaduri SB, Bredzinski X, Boddu SH (2015) Masking the bitter taste of injectable lidocaine HCl formulation for dental procedures. AAPS PharmSciTech 16:455–465CrossRefGoogle Scholar
  65. You P, Yuan R, Chen C (2017) Design and evaluation of lidocaine- and prilocaine-coloaded nanoparticulate drug delivery systems for topical anesthetic analgesic therapy: a comparison between solid lipid nanoparticles and nanostructured lipid carriers. Drug Des Devel Ther 11:2743–2752CrossRefGoogle Scholar
  66. Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S, study i (2017) Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol 16:291–300CrossRefGoogle Scholar
  67. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109–110CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Stéphani Batista de Oliveira
    • 1
  • Erika Ivanna Araya
    • 1
  • Eder Gambeta
    • 1
  • Luiz Eduardo Nunes Ferreira
    • 2
  • Michele Franz-Montan
    • 3
  • Rafaela Franco Claudino
    • 1
  • Juliana Geremias Chichorro
    • 1
    Email author return OK on get
  1. 1.Department of Pharmacology, Biological Sciences SectorFederal University of ParanaCuritibaBrazil
  2. 2.School of NurseGuarulhos UniversityGuarulhosBrazil
  3. 3.Department of Physiological Sciences, Piracicaba Dental SchoolUniversity of CampinasSao PauloBrazil

Personalised recommendations